NYSE · INCY
Healthcare · Biotechnology
$112.79
Up+$0.04 (+0.04%)
Updated Oct 10, 2026, 5:55 PM
SID Score
6.0/10
Composite research score
Smart Money
58/100
Neutral
Price performance · INCY
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 9, 2026
INCY closed at $112.79 after 21 trading sessions, down 7.15% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 9, 2026 | $112.35 | $113.87 | $111.805 | $112.79 | 1.12M |
| Oct 8, 2026 | $112.89 | $113.75 | $110.08 | $112.75 | 1.93M |
| Oct 7, 2026 | $112.82 | $115.49 | $112.455 | $113.44 | 1.27M |
| Oct 6, 2026 | $114.13 | $114.9651 | $111.67 | $112.73 | 2.46M |
| Oct 5, 2026 | $115.145 | $115.67 | $112.83 | $114.13 | 1.95M |
| Oct 2, 2026 | $116.76 | $117.19 | $114.57 | $115.30 | 2.17M |
| Oct 1, 2026 | $120.47 | $121.22 | $117.00 | $117.14 | 2.36M |
| Sep 30, 2026 | $123.00 | $124.2299 | $121.03 | $121.35 | 1.62M |
| Sep 29, 2026 | $123.67 | $125.47 | $121.89 | $123.20 | 1.72M |
| Sep 28, 2026 | $123.32 | $126.14 | $122.5295 | $124.82 | 1.44M |
| Sep 25, 2026 | $125.72 | $126.00 | $123.07 | $123.89 | 1.21M |
| Sep 24, 2026 | $124.79 | $125.5489 | $123.03 | $124.44 | 1.4M |
| Sep 23, 2026 | $127.51 | $128.21 | $123.89 | $124.64 | 1.53M |
| Sep 22, 2026 | $124.72 | $127.75 | $124.01 | $126.93 | 1.65M |
| Sep 21, 2026 | $125.00 | $127.41 | $124.1893 | $124.65 | 1.27M |
| Sep 18, 2026 | $127.85 | $128.72 | $125.23 | $125.31 | 3.7M |
| Sep 17, 2026 | $125.74 | $127.74 | $125.10 | $127.62 | 1.47M |
| Sep 16, 2026 | $121.48 | $124.96 | $121.48 | $124.75 | 1.35M |
| Sep 15, 2026 | $121.58 | $122.19 | $119.97 | $121.74 | 1.56M |
| Sep 14, 2026 | $122.48 | $123.345 | $121.28 | $122.19 | 1.46M |
| Sep 11, 2026 | $124.35 | $124.35 | $121.42 | $121.47 | 1.43M |
The latest Smart Investors Daily articles mentioning INCY.
Company
Market Activity
Research & News
INCY research
Company profile and research snapshot.
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 8, 2026 | RBC Capital | Sector Perform | — |
| Oct 5, 2026 | Stifel | Buy | — |
| Oct 1, 2026 | Wells Fargo | Equal-Weight | — |
| Sep 28, 2026 | JP Morgan | Neutral | — |
| Sep 28, 2026 | HC Wainwright & Co. | Buy | — |
No generated briefing is available yet.
Yahoo · Oct 1, 2026
The end of the earnings season is always a good time to take a step back and see who shined (and who didn’t). Let’s take a look at how biotechnology stocks fared in Q2, starting with Incyte (NASDAQ:INCY).
Benzinga · Oct 1, 2026
Incyte (NASDAQ:INCY) has outperformed the market over the past 20 years by 8.48% on an annualized basis producing an average annual return of 17.52%. Currently, Incyte has a market capitalization of $23.82 billion.
Benzinga · Oct 1, 2026
Wells Fargo analyst Derek Archila maintains Incyte (NASDAQ:INCY) with a Equal-Weight and raises the price target from $116 to $128.
ChartMill · Sep 30, 2026
INCY stock clears high growth momentum and technical screens with strong EPS growth, rising margins, and a constructive chart setup near a potential breakout.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning INCY.
